BioCryst gets BARDA contract to produce new treatment; Mutual recalls drug made for Sun;

> The Biomedical Advanced Research and Development Authority (BARDA) has awarded BioCryst Pharmaceuticals a $35 million contract to develop and manufacture, a potential treatment for diseases caused by RNA pathogens, including filoviruses. Report 

> Mylan ($MYL) is recalling more than 935 vials of DOXOrubicin Hydrochloride Injection, manufactured for it in India by Onco Therapies after a vial of Ifosfamide Injection was found in a pack. Report

> Mutual Pharmaceutical Company is recalling 23,246 bottles of ergoloid mesylates that it manufactured for Sun Pharmaceutical after the drug for dizziness failed long-term impuriies testing. Report

> Greenville, NC-based CDMO Metrics Contract Services has invested $200,000 in equipment that will help clients to meet higher standards of impurities testing. Release

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.